Usefulness of antiplatelet drugs in ischaemic stroke prevention--update on new trials.
Meta-analysis shows that the absolute risk reduction of antiplatelet therapy for the prevention of fatal and non-fatal stroke is only 1%. This stresses the need for further studies that explore the use of combination therapy and focus on more homogeneous stroke populations such as acute-stroke patients. Recent studies are reviewed that extended the database on antiplatelet drugs in ischaemic stroke prevention.